183 related articles for article (PubMed ID: 28108367)
21. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
[TBL] [Abstract][Full Text] [Related]
22. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
[TBL] [Abstract][Full Text] [Related]
23. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
24. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Velez Perez AL; Schmidt-Malan SM; Kohner PC; Karau MJ; Greenwood-Quaintance KE; Patel R
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):356-359. PubMed ID: 27130477
[TBL] [Abstract][Full Text] [Related]
26. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
27. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
28. Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
Pournaras S; Ikonomidis A; Neou E; Kantzanou M; Maniatis AN; Tsakris A
J Antimicrob Chemother; 2008 Mar; 61(3):757-8. PubMed ID: 18199562
[No Abstract] [Full Text] [Related]
29. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
Gagliotti C; Sarti M; Sabia C; Gargiulo R; Rossolini GM; Carillo C; Cassani C; Cipolloni AP; Pedna F; Rossi MR; Incerti SS; Testa G; Venturelli C; Moro ML
New Microbiol; 2011 Jan; 34(1):97-9. PubMed ID: 21344153
[TBL] [Abstract][Full Text] [Related]
31. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey.
Ozgumus OB; Caylan R; Tosun I; Sandalli C; Aydin K; Koksal I
Microb Drug Resist; 2007; 13(3):191-8. PubMed ID: 17949306
[TBL] [Abstract][Full Text] [Related]
32. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
34. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
35. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic evaluation of piperacillin-tazobactam.
Hayashi Y; Roberts JA; Paterson DL; Lipman J
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
[TBL] [Abstract][Full Text] [Related]
37. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
39. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
Sugimoto N; Yamagishi Y; Mikamo H
J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis.
Pathengay A; Mathai A; Shah GY; Ambatipudi S
J Cataract Refract Surg; 2010 Dec; 36(12):2210-1. PubMed ID: 21111328
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]